With the FDA approval of its zongertinib in certain non-small cell lung cancer (NSCLC) patients, 175-year-old Boehringer ...

Christina Poh, MD, of City of Hope National Medical Center, highlights the benefit of tafasitamab in improving progression-free survival for heavily pretreated patients with relapsed or refractory ...

Epkinly with Rituxan and Revlimid, compared to Rituxan and Revlimid alone, reduced risk of progression or death by 79%.

Less than one-quarter of next-in-class cancer drugs demonstrated a survival benefit over existing in-class agents in head-to-head trials.

Epcoritamab shows promising results in treating relapsed follicular lymphoma, with FDA priority review for a groundbreaking ...

A study reveals real-world outcomes of neoadjuvant immune checkpoint inhibitors in nonmetastatic colon cancer, highlighting ...

Since 1990, the global incidence of early-onset cancer has risen by 80 percent. Oncologists share what's behind the rising ...

A recent study reveals that some colon cancer cells revert to a fetal-like state, enabling them to resist chemotherapy. This ...

New research reveals that updated colorectal cancer screening among younger Americans has led to significant increases in local-stage tumor detection and diagnoses.

Compugen advances COM701 in ovarian cancer with strong partners, key catalysts ahead, and funding into 2027. Find out why ...

Unfortunately, most early signs of colon cancer are often ignored because they mimic less serious conditions. Below we list ...